Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Nan Zhang, Yanliang Zhang, PhD, Xia Cao, MSc, Irina Krapf, MSc, Qingdong Mark Deng, Angel Wei, MD, Jerome B. Zeldis, MD PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 1942.

https://doi.org/10.1182/blood-2019-131892

Published: 2019

Journal Articles

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

Caron A. Jacobson, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Daniel J. DeAngelo, MD, Christopher Heery, MD, Anthony Stein, MD, Michael D. Jain, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 4107.

https://doi.org/10.1182/blood-2019-128203

Published: 2019

Journal Articles

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Blood (2019) 134 (Supplement_1): 4434.

https://doi.org/10.1182/blood-2019-130584

Published: 2019

Journal Articles

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Yik Andy Yeung, PhD, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, PhD, Kris Poulsen, Ivana Djuretic, PhD, Thomas Van Blarcom, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD

Blood (2019) 134 (Supplement_1): 3921.

https://doi.org/10.1182/blood-2019-129025

Published: 2019

Journal Articles

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Irina Krapf, MSc, Yanliang Zhang, PhD, Nan Zhang, Qingdong Mark Deng, Angel Wei, MD, Robert D. Knight, MD, Jerome B. Zeldis, MD PhD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 4444.

https://doi.org/10.1182/blood-2019-131586

Published: 2019

Journal Articles

Investigation of Allocar T TM Targeting CD70 As a Potential Therapy for an Array of Hematological Malignancies

Siler Panowski, PhD, Surabhi Srinivasan, MS, Thomas Van Blarcom, PhD, Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Thomas Pertel, PhD, Marianne A Santaguida, PhD, Roman Galetto, PhD, Alan Dunlop, BSc, MSc, Reuben Benjamin, MD, Barbra Sasu, PhD

Blood (2019) 134 (Supplement_1): 5157.

https://doi.org/10.1182/blood-2019-128808

Published: 2019

Journal Articles

Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL

Jason M Gehrke, PhD, Aaron Edwards, MS, Ryan C. Murray, MS, Amy Shaw, MS, Yeh-Chuin Poh, PhD, Sarah Smith, Yi Yu, PhD, Nicole M. Gaudelli, PhD, Waseem Qasim, MBBS, PhD, Giuseppe Ciaramella, PhD, B.Sc.

Blood (2019) 134 (Supplement_1): 5127.

https://doi.org/10.1182/blood-2019-130562

Published: 2019

Journal Articles

Development of T-Cell Therapy Targeting Hematopoietic Minor Histocompatibility Antigen HA-1

Artem Pilunov, MSc, Dmitrii Romaniuk, MSc, Savely Sheetikov, MSc, Alexandra Khmelevskaya, Anton Shmelev, PhD, Nadia Bykova, Alina Shomuradova, Dmitry Olegovych Kiryukhin, Dmitry Dianov, Grigory Aleksandrovich Efimov, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5749.

https://doi.org/10.1182/blood-2019-130552

Published: 2019

Journal Articles

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Blood (2019) 134 (Supplement_1): 2659.

https://doi.org/10.1182/blood-2019-126869

Published: 2019

Journal Articles

Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies

Kathy Karasiewicz, MSc, Shuyang He, PhD, Mary Ng, MSc, Kristina Tess, Weifang Ling, PhD, Gunnar F. Kaufmann, PhD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 3222.

https://doi.org/10.1182/blood-2019-130782

Published: 2019

Journal Articles

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Charlotte Graham, MRCP, BSc, MBBS, Agnieszka Jozwik, PhD, Ruby Quartey-Papafio, Nikolaos Ioannou, PhD MSc, BSc, Ana M Metelo, PhD, Carlo Scala, PhD, Glenda Dickson, PhD, Orla Stewart, Maria Almena-Carrasco, Elisa Peranzoni, Alan G. Ramsay, BSc,MSc,PhD, Sandra Dupouy, Pharm.D, PhD, Farzin Farzaneh, PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Andrea Pepper, PhD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3228.

https://doi.org/10.1182/blood-2019-123018

Published: 2019

Journal Articles

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Karl W. Staser, MD PhD, Matthew L. Cooper, PhD, Jaebok Choi, PhD, Anand Chukka, Kidist Ashami, BA, Jessica Niswonger, Jaehan Park, Byung Ha Lee, PhD, Shunqiang Li, PhD, Amanda F Cashen, MD, Amy Musiek, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 340.

https://doi.org/10.1182/blood-2018-99-119375

Published: 2018

Journal Articles

Multiplex Human T Cell Engineering without Double-Strand Break Induction Using the Cas9 Base Editor System

Beau Webber, PhD, Cara-lin Lonetree, MS, Miechaleen Diers, Walker S Lahr, Kluesner Mitchell, Matthew J Johnson, PhD, Branden S Moriarity, PhD

Blood (2018) 132 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2018-99-120372

Published: 2018

Journal Articles

Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma

Henia Dar, Daniel Henderson, Zinkal Padalia, MS, Ashley Porras, Dakai Mu, MS, Maeng Kyungah, PhD, Seshidhar Police, PhD, Demetrios Kalaitzidis, PhD, Jonathan Terrett, PhD, Jason Sagert, PhD

Blood (2018) 132 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2018-99-116443

Published: 2018

Journal Articles

Generation of Memory Stem T Cells Specific for Tumor Antigens and Resistant to Inhibitory Signals By Genome Editing

Beatrice Claudia Cianciotti, Alessia Potenza, Valentina Vavassori, Zulma Magnani, Luigi Naldini, MD PhD, Fabio Ciceri, MD, Pietro Genovese, PhD, Eliana Ruggiero, PhD, Chiara Bonini, MD

Blood (2018) 132 (Supplement 1): 2202.

https://doi.org/10.1182/blood-2018-99-118201

Published: 2018

Journal Articles

A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing

Matt L Cooper, PhD, Karl W. Staser, MD PhD, Julie Ritchey, Jessica Niswonger, Byung Ha Lee, PhD, Jaehan Park, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2199.

https://doi.org/10.1182/blood-2018-99-117265

Published: 2018

Journal Articles

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Blood (2018) 132 (Supplement 1): 4546.

https://doi.org/10.1182/blood-2018-99-116843

Published: 2018

Journal Articles

ALLO-819, an Allogeneic Flt3 CAR T Therapy Possessing an Off-Switch for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Ivana Djuretic, PhD, Julien Valton, PhD, Duy Nguyen, Janette Sutton, Kris Poulsen, Julianne Smith, PhD, Ivana Djuretic, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD

Blood (2018) 132 (Supplement 1): 3335.

https://doi.org/10.1182/blood-2018-99-117605

Published: 2018

Journal Articles

Calibrated CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency

Judith Feucht, MD, Jie Sun, PhD, Justin Eyquem, PhD, Yu-Jui Ho, PhD, Zeguo Zhao, PhD, Josef Leibold, MD, Anton Dobrin, Annalisa Cabriolu, PhD, Mohamad Hamieh, PhD, Michel Sadelain, MD PhD

Blood (2018) 132 (Supplement 1): 1412.

https://doi.org/10.1182/blood-2018-99-117698

Published: 2018

NARROW

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Investigation of Allocar T TM Targeting CD70 As a Potential Therapy for an Array of Hematological Malignancies

Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL

Development of T-Cell Therapy Targeting Hematopoietic Minor Histocompatibility Antigen HA-1

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Multiplex Human T Cell Engineering without Double-Strand Break Induction Using the Cas9 Base Editor System

Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma

Generation of Memory Stem T Cells Specific for Tumor Antigens and Resistant to Inhibitory Signals By Genome Editing

A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

ALLO-819, an Allogeneic Flt3 CAR T Therapy Possessing an Off-Switch for the Treatment of Acute Myeloid Leukemia

Calibrated CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only